Gibraltar

There is no population-wide dementia screening program. Consistent with UK and international guidance, Gibraltar prioritizes awareness, early recognition, and GP-led case-finding, supported by training targets and referral guidance within the national strategy.

Structural brain imaging (CT and MRI) is available through public radiology at St Bernard’s Hospital and private providers such as GibMed International Hospital, enabling timely exclusion of secondary causes and support for differential diagnosis. Initially limited to a maximum of four GHA patients per day despite higher capacity, GibMed’s scanner has mainly been used for head and musculoskeletal imaging, with the GHA continuing to send some cases to Spain while it reviews longer-term in-house MRI provision at St Bernard’s Hospital. PET imaging for dementia is not described as routine locally and would generally require off-territory referral.

Gibraltar does not have a publicly articulated Alzheimer’s or dementia genetics policy, and the National Dementia Strategy 2023–2028 does not commit to routine genetic testing as part of the diagnostic pathway. There is no population-level or family-based genetic screening program, and testing for autosomal dominant Alzheimer’s disease (e.g. APP, PSEN1, PSEN2) or risk alleles such as APOE ε4 is not described in government or GHA guidance. Where genetics are considered clinically relevant, typically in cases of early-onset dementia or strong familial history, testing is initiated case-by-case by specialists, often requiring referral to private or overseas laboratories (most commonly in the UK or Spain). Genetic counselling is not formally described as a dedicated local service and would usually be coordinated through specialist referral pathways rather than embedded primary care.

The national strategy does not include a commitment to routine biomarker-based diagnosis of dementia. Cerebrospinal fluid (CSF) biomarkers and emerging blood-based assays are therefore not part of standard clinical practice in Gibraltar. Their use, when pursued, is specialist-led and selective, typically in diagnostically complex cases or where confirmation would meaningfully alter management. Access to CSF analysis or advanced biomarker testing generally requires external referral through established GHA processes, including the Sponsored Patients route where approved. PET for amyloid or tau imaging is not described as locally available or routine, reinforcing Gibraltar’s continued reliance on clinical assessment and structural imaging (CT or MRI) as the diagnostic backbone, consistent with pragmatic small-system models.

Dementia care in Gibraltar is delivered through a compact, highly integrated public network, reflecting the territory’s single-city geography and NHS-derived service model. Core provision is coordinated by the GHA and includes the Primary Care Centre (as the universal entry point), Memory Clinic and community mental-health teams, Elderly Residential Services (ERS), the Care Agency, and a range of home-based and community support packages. The National Dementia Strategy explicitly aims to reduce fragmentation by promoting single-point access, continuity of care across disease stages, and early deployment of home support to delay or avoid institutionalization. Because all services are concentrated within one urban area, geographical access barriers are minimal. Instead, system resilience depends on coordination, staffing capacity, and integration with voluntary partners.

A defining feature of Gibraltar’s model is the formal integration of NGO support alongside statutory services. The Gibraltar Alzheimer’s & Dementia Society (GADS) provides education, helplines, peer support, and community awareness initiatives such as Dementia Friends, effectively filling psychosocial and navigation gaps that small public systems often struggle to cover alone. This partnership approach allows the GHA to focus on clinical and social-care delivery while NGOs sustain caregiver engagement, stigma reduction, and early help-seeking.

The Dementia Strategy 2023–2028 places renewed emphasis on palliative and end-of-life care, recognizing dementia as a life-limiting condition rather than solely a cognitive disorder. Within ERS and GHA community services, palliative provision has been strengthened through specialist nursing input, anticipatory care planning, and enhanced home-support packages for advanced disease. While Gibraltar does not operate a stand-alone dementia palliative service, palliative principles are increasingly embedded within existing elderly and community care structures, aiming to improve symptom control, reduce avoidable hospitalization, and support families through later disease stages.

For entitled residents, dementia medicines on the GHA formulary are subsidized, with patients paying low, fixed co-payments per prescription item, rather than full market prices. This mirrors the UK NHS approach and helps limit financial barriers to long-term treatment adherence. Higher-risk or more complex dementia drugs remain specialist-only for initiation, ensuring clinical oversight and cost control. By contrast, medicines prescribed privately, branded alternatives outside the formulary, or care accessed through private providers are paid out-of-pocket, unless exceptional funding is approved under established government mechanisms.

Caregiver support is a core pillar of Gibraltar’s dementia strategy. The GHA commits to single-point access, improved navigation, and structured caregiver education, recognizing families as the primary providers of day-to-day dementia care. Formal signposting includes promotion of WHO iSupport, offering evidence-based digital training and coping tools for carers. In parallel, GADS delivers locally embedded support such as peer groups, helplines, public talks, and Dementia Friends training, creating a blended model where statutory services address clinical and social-care needs, while NGOs sustain emotional support, community resilience, and dementia literacy.

Gibraltar’s National Dementia Strategy 2023–2028 provides the current overarching policy framework for dementia, built as a multi-agency program involving the GHA, ERS, the Care Agency, Housing services, and the GADS. The strategy explicitly builds on lessons from the 2018–2021 dementia strategy, shifting from an initial awareness phase toward system integration and quality improvement. It is closely aligned with the WHO Global Action Plan on the Public Health Response to Dementia, particularly in its emphasis on awareness, timely diagnosis, community-based care, and caregiver support.
The strategy is structured around four core objectives. First, it prioritizes awareness raising and stigma reduction, recognizing that in a small and socially dense population, fear, denial, and informal coping can delay help-seeking. Second, it focuses on earlier diagnosis, operationalized through GP-led case-finding, clearer referral thresholds, and structured access to the Memory Clinic. Third, it aims to support people with dementia to live well at home for as long as possible, through flexible home-support packages, care coordination, and adaptations to housing and community services. Fourth, it commits to improved end-of-life and palliative care, explicitly framing dementia as a progressive, life-limiting condition requiring anticipatory planning rather than crisis-driven intervention.

Rather than launching a successor policy, Gibraltar’s stated priority is full implementation of the 2023–2028 strategy. Planned and ongoing actions include territory-wide awareness campaigns, continued roll-out of Dementia Friends training across public services and the community, and targeted staff training within health, social care, and residential settings. The strategy also envisages expansion of peer-support networks and closer operational integration with GADS, reinforcing non-clinical support structures alongside statutory care. Within primary care, implementation efforts focus on GP education, dementia case-finding targets, and referral consistency, aiming to reduce diagnostic delay while avoiding unnecessary specialist bottlenecks. Collectively, these measures reflect a pragmatic small-system approach: improving quality and consistency of existing services rather than creating new institutional layers.

Innovation in Gibraltar’s dementia response is systemic and social rather than biomedical, reflecting a deliberate policy choice shaped by the territory’s small population, single-city geography, and limited research infrastructure. Rather than attempting to replicate large-scale academic or laboratory-driven models, Gibraltar focuses on optimizing how existing services interact, how early signs are recognized, and how people with dementia and their families experience the system as a whole. Innovation is therefore framed as service design, coordination, and community adaptation, not technological novelty.

A central pillar of this approach is the development of a dementia-friendly community. This includes awareness campaigns, Dementia Friends training, and efforts to normalize dementia in everyday public settings such as shops, workplaces, and public services. In a close-knit society, these measures aim to reduce stigma, encourage earlier disclosure of symptoms, and foster informal support networks that complement formal care. Community-level adaptation is treated as a form of innovation in its own right, recognizing that social attitudes and everyday interactions strongly shape quality of life in dementia.

At the clinical interface, innovation focuses on strengthening GP-led case-finding and referral performance. Rather than introducing population screening or advanced diagnostics, the system invests in GP training, clearer referral thresholds, and feedback loops with the Memory Clinic to reduce diagnostic delay and variation in practice. This reinforces primary care as the system’s diagnostic backbone and ensures that limited specialist capacity is used efficiently. Improvements in referral quality are seen as a higher-yield intervention than expanding specialist diagnostics in a small system.

Structured carer education and support represents another core innovation stream. The promotion of WHO iSupport provides carers with evidence-based tools for managing behavioural symptoms, stress, and care planning, while NGO-led peer support translates this knowledge into local practice. This emphasis reflects recognition that caregivers deliver the majority of dementia care and that relatively modest investments in training and support can produce disproportionate gains in patient stability, reduced crises, and delayed institutionalization.